GILD

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

MoonshotScore Breakdown: 57.5/100

📰 Latest News

Gilead Sciences pioneers innovative therapies for life-threatening diseases, holding a dominant position in HIV/AIDS treatment and expanding its oncology and liver disease portfolios, offering investors a blend of stable revenue and growth potential with a 2.07% dividend yield.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. The company's portfolio addresses unmet medical needs in HIV/AIDS, liver diseases, oncology, and other therapeutic areas.

Gilead Sciences, Inc. Company Overview

Gilead Sciences, Inc., founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for areas of unmet medical need. Initially focused on antiviral therapies, Gilead achieved prominence with its groundbreaking treatments for HIV/AIDS, transforming the landscape of the disease from a death sentence to a manageable condition. Key HIV/AIDS products include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. The company further expanded its portfolio to address liver diseases, including hepatitis B and C, with products like Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Gilead's acquisition of Kite Pharma in 2017 marked a significant entry into the field of oncology and cell therapy, adding Yescarta and Tecartus to its offerings. Other products include Trodelvy for cancer treatment, Zydelig for hematological malignancies, Letairis for pulmonary arterial hypertension, Ranexa for chronic angina, and AmBisome for serious fungal infections. Gilead operates globally, with a presence in the United States, Europe, and other international markets. The company actively engages in collaborations with other biotechnology and pharmaceutical companies, including Arcus Biosciences, Inc., Bristol-Myers Squibb Company, and Merck & Co., Inc., to advance its research and development efforts and expand its therapeutic pipeline.

Investment Thesis

Gilead Sciences presents a compelling investment opportunity due to its established dominance in the HIV/AIDS treatment market, generating consistent revenue and cash flow. The company's expansion into oncology and liver diseases provides significant growth potential. With a solid financial foundation, indicated by a profit margin of 27.9% and a gross margin of 78.7%, Gilead is well-positioned to invest in research and development and strategic acquisitions. Key growth catalysts include the continued uptake of Biktarvy, advancements in its oncology pipeline, and successful collaborations with partners. The company's commitment to innovation and addressing unmet medical needs makes it an attractive long-term investment, further supported by a 2.07% dividend yield.

Key Financial Highlights

• Market Cap of $189.20B reflects Gilead's significant presence in the biopharmaceutical industry.
• P/E ratio of 23.37 indicates investor confidence in Gilead's earnings potential.
• Profit Margin of 27.9% demonstrates Gilead's ability to generate substantial profits from its revenue.
• Gross Margin of 78.7% highlights the efficiency of Gilead's operations and pricing power.
• Dividend Yield of 2.07% provides investors with a steady stream of income.

Industry Context

Gilead Sciences operates within the dynamic and competitive drug manufacturing industry. The industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition from both established pharmaceutical companies and emerging biotechnology firms. The market is driven by factors such as an aging global population, increasing prevalence of chronic diseases, and advancements in medical technology. Gilead competes with companies like Amgen (AMGN), Bristol-Myers Squibb (BMY), and GlaxoSmithKline (GSK) in various therapeutic areas. The global pharmaceuticals market is projected to reach trillions of dollars in the coming years, presenting significant growth opportunities for companies like Gilead that can successfully innovate and bring new therapies to market.

Quarterly Financial Summary

Source: Company filings. Data may be delayed.

Growth Opportunities

• Expansion in Oncology: Gilead's acquisition of Kite Pharma provides a strong foundation for growth in the oncology market. The cell therapy market is projected to reach $76.4 billion by 2030. Gilead can leverage its expertise in cell therapy and develop new treatments for various types of cancer, driving revenue growth in the coming years.
• Advancements in HIV Treatment: Despite its dominance in the HIV treatment market, Gilead continues to innovate and develop new therapies with improved efficacy and convenience. The global HIV treatment market is expected to continue growing, driven by increasing awareness and access to treatment. Gilead can maintain its leadership position by introducing next-generation HIV therapies.
• Growth in Liver Disease Therapies: Gilead has a strong portfolio of therapies for liver diseases, including hepatitis B and C. The global market for liver disease treatments is expected to grow, driven by increasing prevalence of these diseases. Gilead can expand its market share by developing new and improved treatments for liver diseases.
• Strategic Collaborations: Gilead has established collaborations with several biotechnology and pharmaceutical companies to expand its research and development pipeline. These collaborations provide access to new technologies and therapeutic candidates, accelerating Gilead's innovation efforts. Successful collaborations can lead to the development of new blockbuster drugs and drive long-term growth.
• Geographic Expansion: Gilead currently operates in the United States, Europe, and other international markets. Expanding its geographic reach into emerging markets, such as Asia and Latin America, can provide significant growth opportunities. These markets have a large and growing population with increasing healthcare needs. Gilead can leverage its existing portfolio and develop new products tailored to the needs of these markets.

Competitive Advantages

• Strong intellectual property protection for its key products.
• Established brand reputation and market leadership in HIV/AIDS treatment.
• Extensive research and development capabilities.
• Strategic collaborations with other biotechnology and pharmaceutical companies.

Strengths

• Dominant position in HIV/AIDS treatment market.
• Strong portfolio of therapies for liver diseases.
• Growing presence in the oncology market through Kite Pharma acquisition.
• Robust research and development pipeline.

Weaknesses

• Reliance on a few key products for a significant portion of revenue.
• Exposure to patent expirations and generic competition.
• High research and development costs.
• Dependence on regulatory approvals for new products.

Opportunities

• Expansion into new therapeutic areas, such as immunology and inflammation.
• Growth in emerging markets.
• Strategic acquisitions and collaborations to expand product portfolio.
• Development of new and improved therapies for existing indications.

Threats

• Increasing competition from other pharmaceutical companies.
• Pricing pressures from government and private payers.
• Unfavorable regulatory changes.
• Product liability lawsuits.

What GILD Does

• Discovers and develops medicines for unmet medical needs.
• Commercializes pharmaceutical products globally.
• Focuses on therapies for HIV/AIDS, liver diseases, and oncology.
• Offers treatments for serious invasive fungal infections.
• Provides therapies for pulmonary arterial hypertension and chronic angina.
• Engages in research and development to expand its product pipeline.
• Collaborates with other companies to advance its therapeutic programs.

Business Model

• Develops and patents proprietary pharmaceutical products.
• Generates revenue through the sale of its medicines.
• Invests heavily in research and development to discover new therapies.
• Partners with other companies to expand its product portfolio and market reach.

Key Customers

• Patients with HIV/AIDS.
• Patients with liver diseases, such as hepatitis B and C.
• Patients with various types of cancer.
• Hospitals and healthcare providers.
• Government healthcare programs.

Competitors

• Amgen Inc. (AMGN): Competes in oncology and other therapeutic areas.
• Bristol-Myers Squibb Company (BMY): Competes in oncology and immunology.
• Boston Scientific Corporation (BSX): Medical device company with some overlapping therapeutic areas.
• Danaher Corporation (DHR): Life sciences and diagnostics company.
• GlaxoSmithKline (GSK): Competes in HIV and other therapeutic areas.

Catalysts

• Upcoming: FDA approval of new oncology therapies in Gilead's pipeline.
• Ongoing: Continued growth in sales of Biktarvy for HIV treatment.
• Ongoing: Positive clinical trial results for new drug candidates.
• Upcoming: Potential acquisitions or collaborations to expand product portfolio.

Risks

• Potential: Patent expirations on key products leading to generic competition.
• Ongoing: Regulatory setbacks or delays in drug approvals.
• Potential: Unsuccessful clinical trials for new drug candidates.
• Ongoing: Pricing pressures and reimbursement challenges.
• Potential: Product liability lawsuits.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Drug Manufacturers - General

Browse More

Next Steps